{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:37:40Z","timestamp":1777934260509,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>Mantle cell lymphoma accounts for 5\u20137% of all non-Hodgkin\u2019s lymphomas. Under the current WHO classification, it is categorized as an indolent B cell lymphoma, but has an aggressive clinical course. New insights into leukemogenic molecular pathways of mantle cell lymphoma have uncovered unique therapeutic targets. Ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, is the newest drug in the arsenal that has shown promising efficacy in relapsed mantle cell lymphoma. Long-term studies have shown that grade 3 or 4 adverse events are infrequent. Asymptomatic lymphocytosis is frequently seen with ibrutinib use in mantle cell lymphoma; however, tumor lysis syndrome is an extremely rare complication. To date, only two patients with ibrutinib-associated tumor lysis syndrome in mantle cell lymphoma have been described in a long-term follow-up study. Both patients met laboratory criteria for tumor lysis syndrome, however, but did not develop clinical tumor lysis syndrome. We, here describe a patient with relapsed mantle cell lymphoma who developed clinical tumor lysis syndrome with ibrutinib monotherapy.<\/jats:p>","DOI":"10.1177\/1078155216637218","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T20:08:49Z","timestamp":1457813329000},"page":"235-239","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report"],"prefix":"10.1177","volume":"23","author":[{"given":"Varinder","family":"Kaur","sequence":"first","affiliation":[{"name":"British Columbia Cancer Agency, Vancouver Island Cancer Center, Victoria, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Swami","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, St. George\u2019s University, Grenada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"key":"bibr1-1078155216637218","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2008","edition":"4"},{"key":"bibr2-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"bibr3-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"bibr4-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"bibr5-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"bibr6-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-591875"},{"key":"bibr7-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07124.x"},{"key":"bibr8-1078155216637218","first-page":"1291","volume":"85","author":"Pileri SA","year":"2000","journal-title":"Haematologica"},{"key":"bibr9-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1126\/science.6610211"},{"key":"bibr10-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880556"},{"key":"bibr11-1078155216637218","first-page":"2253","volume":"95","author":"Yatabe Y","year":"2000","journal-title":"Blood"},{"key":"bibr12-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1753"},{"key":"bibr13-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.140"},{"key":"bibr14-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093401"},{"key":"bibr15-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"bibr16-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"bibr17-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403566"},{"key":"bibr18-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"bibr19-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"bibr20-1078155216637218","first-page":"141","volume":"34","author":"Pighi C","year":"2011","journal-title":"Cell"},{"key":"bibr21-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-2-4"},{"key":"bibr22-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"bibr23-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"bibr24-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090010007001"},{"key":"bibr25-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(77)90191-5"},{"key":"bibr26-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"},{"key":"bibr27-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.697"},{"key":"bibr28-1078155216637218","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216637218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155216637218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216637218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:45Z","timestamp":1777688205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155216637218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1177\/1078155216637218"],"URL":"https:\/\/doi.org\/10.1177\/1078155216637218","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,23]]}}}